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DOI 10.1186/s13075-015-0651-0RESEARCH ARTICLE Open AccessThe preclinical pharmacology of the high
affinity anti-IL-6R Nanobody® ALX-0061 supports
its clinical development in rheumatoid arthritis
Maarten Van Roy1*, Cedric Ververken1, Els Beirnaert1,2, Sven Hoefman1, Joost Kolkman1,3, Michel Vierboom4,
Elia Breedveld4, Bert ‘t Hart4,5, Sofie Poelmans1, Lieselot Bontinck1, Alex Hemeryck1, Sandy Jacobs1, Judith Baumeister1
and Hans Ulrichts1Abstract
Introduction: The pleiotropic cytokine interleukin-6 (IL-6) plays an important role in the pathogenesis of different
diseases, including rheumatoid arthritis (RA). ALX-0061 is a bispecific Nanobody® with a high affinity and potency
for IL-6 receptor (IL-6R), combined with an extended half-life by targeting human serum albumin. We describe here
the relevant aspects of its in vitro and in vivo pharmacology.
Methods: ALX-0061 is composed of an affinity-matured IL-6R-targeting domain fused to an albumin-binding domain
representing a minimized two-domain structure. A panel of different in vitro assays was used to characterize the biological
activities of ALX-0061. The pharmacological properties of ALX-0061 were examined in cynomolgus monkeys, using plasma
levels of total soluble (s)IL-6R as pharmacodynamic marker. Therapeutic effect was evaluated in a human IL-6-induced
acute phase response model in the same species, and in a collagen-induced arthritis (CIA) model in rhesus monkeys,
using tocilizumab as positive control.
Results: ALX-0061 was designed to confer the desired pharmacological properties. A 200-fold increase of target affinity
was obtained through affinity maturation of the parental domain. The high affinity for sIL-6R (0.19 pM) translated to a
concentration-dependent and complete neutralization of sIL-6R in vitro. In cynomolgus monkeys, ALX-0061 showed a
dose-dependent and complete inhibition of hIL-6-induced inflammatory parameters, including plasma levels of C-reactive
protein (CRP), fibrinogen and platelets. An apparent plasma half-life of 6.6 days was observed after a single
intravenous administration of 10 mg/kg ALX-0061 in cynomolgus monkeys, similar to the estimated expected
half-life of serum albumin. ALX-0061 and tocilizumab demonstrated a marked decrease in serum CRP levels in a
non-human primate CIA model. Clinical effect was confirmed in animals with active drug exposure throughout
the study duration.
Conclusions: ALX-0061 represents a minimized bispecific biotherapeutic of 26 kDa, nearly six times smaller
than monoclonal antibodies. High in vitro affinity and potency was demonstrated. Albumin binding as a half-life extension
technology resulted in describable and expected pharmacokinetics. Strong IL-6R engagement was shown to translate to
in vivo effect in non-human primates, demonstrated via biomarker deregulation as well as clinical effect. Presented results
on preclinical pharmacological properties of ALX-0061 are supportive of clinical development in RA.* Correspondence: maarten.vanroy@ablynx.com
1Ablynx NV, Technologiepark 21, 9052 Zwijnaarde, Belgium
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Rheumatoid arthritis (RA) is a chronic, debilitating dis-
order with a prevalence believed to range from 0.5 to 1.0 %
in the general population [1, 2]. Various disease-modifying
antirheumatic drugs (DMARDs) have been in clinical use
for decades to control the disease symptoms. However,
there has been a paradigm shift in RA therapy during the
past decades: current treatment aims at persistent and
complete disease suppression, resulting in remission
[1, 3, 4]. Although the use of tumor necrosis factor (TNF)
inhibitors has revolutionized RA treatment in that aspect, a
high number of patients still fail to achieve remission and
do not show significant improvement [4]. Treatment
response is thought to be heterogeneous in patients due to
the relative dominance of a specific biological pathway or
cellular phenotype [5, 6], and inhibition of the interleukin
6-interleukin 6 receptor (IL-6-IL-6R) axis has emerged as a
powerful alternative, as demonstrated by tocilizumab (TCZ)
[7, 8] and several other compounds in development [8].
IL-6 is a pleiotropic and key pro-inflammatory cytokine
involved in the systemic inflammation and joint destruction
observed in RA [9, 10]. The biological activity of IL-6 is
mediated via a hexameric signaling complex, consisting of
two molecules each of IL-6, IL-6R and glycoprotein 130.
Formation of this complex leads to activation of the intra-
cellular Janus kinase (JAK) / signal transducer and activator
of transcription (STAT)-3, Ras/mitogen activated protein
kinase (MAPK) or phosphoinositide 3-kinase (PI3K) / Akt
pathway. Unlike other cytokines, IL-6 can initiate this sig-
naling cascade through binding to either membrane-bound
receptor (mIL-6R; classical signaling) or soluble receptor
(sIL-6R; trans-signaling). IL-6 plays a critical role in differ-
ent aspects of RA, such as the transition from the acute
phase of inflammation to the chronic irreversible stage [11],
stimulation of B cells to produce auto-antibodies, cartilage
destruction [12] and anemia [13].
Nanobodies® are therapeutic proteins based on the
smallest functional fragments of heavy chain-only (VHH)
antibodies, naturally occurring in the Camelidae family
[14–16]. In the present study we describe aspects of the
preclinical development of the Nanobody® ALX-0061,
consisting only of two domains which sufficed to confer
the desired properties in vitro and in vivo. One domain
of ALX-0061 was directed against IL-6R in order to in-
hibit the pro-inflammatory activities of the IL-6 pathway.
The second domain was designed to improve the phar-
macokinetic (PK) properties of the Nanobody by binding
to human serum albumin (HSA). This format constitutes
a minimized design, yielding a small structure which
conveys high potency, as well as promising PK proper-
ties and in vivo efficacy. ALX-0061 was characterized
using in vitro systems assessing affinity and potency. In
vivo efficacy and pharmacodynamic (PD) properties were
studied in an acute human IL-6 (hIL-6)-inducedinflammation model in cynomolgus monkeys, and in a
collagen-induced arthritis (CIA) model in rhesus monkeys.
Methods
Materials
ALX-0061 is a half-life extended bispecific Nanobody
consisting of two sequence-optimized variable domains
of llama-derived VHH antibodies, directed against IL-6R
and HSA, which were genetically fused via nine amino
acids (GGGGSGGGS).
ALX-0061 and the monovalent anti-IL-6R domain were
produced in a Pichia pastoris strain (Thermo Fisher Scien-
tific, Waltham, MA) that expresses and secretes the Nano-
body into the medium. The yeast cells were separated from
the medium by centrifugation. The medium was subse-
quently clarified by depth filtration, after which the product
was further purified using a process comprising three chro-
matographic steps. ALX-0061 was formulated in 15 mM L-
Histidine (Sigma-Aldrich, St. Louis, MO), 8 % sucrose (234
mM; Fluka, Sigma-Aldrich, St. Louis, MO), and 0.01 %
Tween-80 (w/w; Merck Chemicals, Darmstadt, Germany)
and at pH 6.5. ALX-0061 was biotinylated (Pierce Biotech-
nology, Rockford, IL, USA), Alexa-fluor-647-tagged (Mo-
lecular Probes, Eugene, OR, USA), or sulfo-tagged (Meso
Scale Discovery, Gaithersburg, MA, USA) according to the
manufacturers’ instructions.
In the CIA study, clinical-grade TCZ (RoActemra®,
20 mg/mL; Roche, Basel, Switzerland) was administered
to the rhesus monkeys undiluted at 0.5 mL/kg (10 mg/kg)
as an intravenous bolus injection at indicated doses.
Affinity maturation
The precursor of the anti-IL-6R domain of ALX-0061
was isolated from a llama immunized with recombinant
hIL-6R (Peprotech, Rocky Hill, NJ, USA), and was subse-
quently humanized followed by affinity maturation.
In a first round of affinity maturation, three libraries of
variants of the humanized Nanobody were screened.
Diversity was introduced by substituting each residue of
the complementarity determining region (CDR)1 and
CDR2 with one or more residues with similar side-chain
chemistry (library one), and in parallel by substituting with
a panel of residues that naturally occur at the given pos-
ition (library two). In a third library, each CDR3 residue
was substituted with one or more residues with similar
side-chain chemistries. Mutagenesis was performed by
PCR overlap extension using degenerated oligonucleo-
tides. The koff values for target binding, as determined via
surface plasmon resonance (SPR), were used to identify
beneficial CDR mutations (see Kinetic analysis).
In a second round of affinity maturation, the beneficial
mutations identified for all three CDRs were combined
into a small library. Detailed koff analysis of the second-
generation Nanobody clones resulted in the selection of
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characterization.
Kinetic analysis
Kinetic analysis of ALX-0061/HSA interactions was per-
formed on a Biacore 3000 instrument (Biacore Inter-
national AB, Uppsala, Sweden). ALX-0061 was injected at
concentrations between 10 and 100 nM onto CM5 sensor
chips (Biacore, GE Healthcare, Little Chalfont, UK), con-
taining immobilized recombinant HSA (Sigma-
Aldrich, St Louis, MO, USA) after amine coupling. Dissoci-
ation was allowed for 300 seconds.
Kinetic analysis of the interactions of the different
Nanobody variants with IL-6R was performed on a Bia-
core T100 instrument (Biacore International AB, Uppsala,
Sweden). For koff measurements, recombinant hsIL-6R
was immobilized via amine coupling on CM5 sensor
chips. Affinity maturation variants were injected onto the
IL-6R surfaces at concentrations up to 200 nM. Dissoci-
ation was allowed for 30 minutes. For on-rate measure-
ments, the non-neutralizing anti-hIL-6R monoclonal
antibody (mAb) B-N12 (Diaclone, Besancon, France) was
first immobilized on the sensor chip via amine coupling.
Recombinant hIL-6R was captured at 100 nM, and the dif-
ferent Nanobody variants were injected onto the B-N12/
IL-6R surfaces at concentrations between 6 and 200 nM.
Affinity analysis of ALX-0061/IL-6R interactions was
performed with the Gyrolab™ Workstation using Gyro-
lab™ Bioaffy 1000 CDs (Gyros®, Upsalla, Sweden). The
Gyrolab CD is a microscale (nanoliter) total analysis sys-
tem with incorporated channels and structures, with im-
munoassay studies as the main present application.
Capillary action and spinning is used for the desired
incubation and washing steps. As a capture tool, 2000
nM of biotinylated recombinant hIL-6R was applied on
the columns of the Bioaffy CDs, which were pre-packed
with streptavidin-coated beads. A dilution series of hIL-6R
was pre-incubated with a fixed concentration of ALX-0061
(50 pM) for 24 hours. This pre-incubation mixture was
subsequently flown over the column, giving residual free
ALX-0061 the opportunity to bind to hIL-6R immobilized
on the column. Bound ALX-0061 was detected with 50 nM
of an Alexa-fluor-647-labeled anti-Nanobody mAb. The
fluorochromes were excited by a red laser, and the obtained
fluorescent signals were amplified by a photo multiplier
tube (PMT). Analysis was performed with the XL fit soft-
ware of the Gyrolab workstation.
Soluble receptor interleukin-6 neutralization potency
ELISA
A non-neutralizing anti-IL-6R Nanobody (20 μg/mL) was
immobilized on 96-well microtiter plates, after which the
coated plates were blocked with Superblock T20 (Thermo-
Fisher Scientific, Waltham, MA, USA). A dilution series ofALX-0061 in the absence or presence of 1 mg/mL HSA
was first pre-incubated for one hour with 100 ng/mL re-
combinant hIL-6 (Gentaur, Kampenhout, Belgium) and 4
ng/mL recombinant hIL-6R, after which the mixtures were
transferred to the coated wells. Bound IL-6R/IL-6 com-
plexes were detected with 100 ng/mL of a biotinylated poly-
clonal anti-hIL-6 mAb (R&D Systems, Minneapolis, MN,
USA), followed by horseradish peroxidase (HRP)-labeled
streptavidin (Dako, Glostrup, Denmark, 1/5,000 or Ther-
moFisher Scientific, Waltham, MA, 1/25,000). Visualization
was performed with esTMB (Stereospecific Detection
Technologies reagents, Baesweiler, Germany), after which
the coloring reaction was stopped with 1 M HCl. The ab-
sorbance was determined at 450 nm using 620 nm as refer-
ence wavelength.Plasma potency ELISA
The non-neutralizing anti-hIL-6R mAb B-N12 (5 μg/mL)
was immobilized on 96-well microtiter plates, after which
the coated plates were blocked with Superblock T20. A di-
lution series of ALX-0061, with 50 ng/mL recombinant
hIL-6 and 50 % human plasma (CryocheckTM, Precision-
BioLogic, Dartmouth, Canada) as a source of sIL-6R, was
first pre-incubated for one hour and was then transferred
to the coated wells. Residual hIL-6 bound to captured
plasma hsIL-6R was detected with 0.2 μg/mL of a biotinyl-
ated polyclonal anti-hIL-6 antibody, followed by HRP-
labeled streptavidin. Visualization was performed as
described above.TF-1 cell-based proliferation assay
The TF-1 cell line (ECACC 93022307; Sigma-Aldrich, St.
Louis, MO) was maintained between 0.5 and 9 × 100,000
cells/mL using RPMI 1640 medium supplemented with
GlutaMAX (Invitrogen, Carlsbad, CA, USA), 10 % fetal
bovine serum (Invitrogen), 1 % sodium pyruvate (Invitro-
gen), 1 % penicillin/streptomycin (Invitrogen) and 3 ng/mL
human granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF; eBiosciences, San Diego, CA, USA).
Cell suspensions were centrifuged, resuspended in culture
medium without GM-CSF and seeded at a density of
12,500 cells/well in a 96-well plate. Cells were subsequently
incubated for two hours with a dilution series of ALX-0061
in the absence or presence of 1 mg/mL recombinant HSA,
after which 2 ng/mL recombinant hIL-6 was added and
cells were further incubated for 72 hours at 37 °C in a
humid chamber under a 5 % CO2 atmosphere. During the
last six hours of the incubation, cells were pulse-labeled
with 0.2 μCi/well of 3H-thymidine (GE Healthcare).
Cells were then harvested and the 3H-thymidine in-
corporation was measured using a Topcount NXT
counter (PerkinElmer, Waltham, MA, USA). Results
were expressed as average counts per minute per well.
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cynomolgus monkeys
This study was conducted in accordance with the require-
ments of UK law (Animals (Scientific Procedures) Act
1986) at the facilities of Covance Inc. (North Yorkshire,
UK). The PK, immunogenicity (anti-drug antibodies
(ADA)) and PD (free and total sIL-6R) of ALX-0061 were
determined after a single intravenous (bolus or infusion)
administration to male cynomolgus monkeys (Macaca fas-
cicularis; Biodia Company Ltd, Port Louis, Mauritius). Dose
levels were 1, 5, 10, 25 and 100 mg/kg and each group con-
sisted of three animals. In addition, two animals were
injected with formulation buffer and served as negative
control. Blood samples were taken at pre-dose and up to 78
days post-administration.
Bioanalytical determination of total active ALX-0061 con-
centrations in plasma samples was performed using a
Dissociation-Enhanced Lanthanide Fluorescent Immuno-
assay (DELFIA; developed at Ablynx, Gent, Belgium). In
brief, a biotinylated bivalent anti-Nanobody Nanobody was
captured onto streptavidin coated plates. Calibrators, qual-
ity control (QC) samples and study samples, complexed
with hIL-6R, were detected with the europium-labelled
non-neutralizing mAb B-N12. The fluorescent europium
signal was measured on a Victor2V 1420 Multilabel Coun-
ter (PerkinElmer, Beaconsfield, UK).
Monkey plasma samples were further evaluated for the
presence of anti-ALX-0061 antibodies using an electro-
chemiluminescent bridging assay (developed at Ablynx,
Gent, Belgium). The same assay format was used for both
screening and confirmation purposes. Briefly, biotinylated
ALX-0061 was used to capture, and sulfo-tagged ALX-
0061 was used to detect ADA in a homogenous assay
format using a MSD Sector Imager 2400 (MesoScale
Discovery, Rockville, MD, USA). Confirmation was
performed by means of specificity testing, inhibiting the
signal by competition with the drug. All samples were
acid-treated before neutralization in the presence of
biotinylated and sulfo-tagged ALX-0061.
Both total and free plasma sIL-6R concentrations were
measured. Total plasma sIL-6R concentrations (that is, free
sIL-6R and sIL-6R in complex with ALX-0061) were
assessed using a sandwich ELISA (developed at Ablynx,
Gent, Belgium). In brief, 96-well microtiter plates were
coated with the capture non-neutralizing mAb B-N12, and
excess binding sites were blocked with phosphate-buffered
saline (PBS) plus 1 % casein. Calibrators, QC samples and
study samples were applied on the plate, after 1/10 dilution
in dilution buffer supplemented with 100 ng/mL ALX-0061
to overcome Nanobody interference. Bound sIL-6R was
detected with a biotinylated polyclonal goat anti-hIL-6R
antibody (R&D Systems), followed by HRP-labeled strepta-
vidin. Visualization was performed as described above. Free
plasma sIL-6R concentrations were measured using aGyrolab™-based assay. In brief, the biotinylated monovalent
anti-IL-6R domain of ALX-0061 was applied onto columns
pre-packed with streptavidin-coated beads. Calibrators, QC
samples and study samples were 1/10 diluted in Rexxip H
buffer (Gyros) and applied onto the CD. After sample trans-
fer, Alexa-fluor-647-labeled B-N12 was added at a concen-
tration of 10 nM in Rexxip F buffer (Gyros). Analysis was
performed as described above, optimized at 5 % PMT.
Human interleukin-6-induced inflammation model in
cynomolgus monkeys
The studies in this model were conducted using ap-
proved protocols, following applicable guidelines for
the care and use of research animals (in accordance
with European Council Directive of 24 November 1986
(86/609/EEG)) at the facilities of Laboratorium für Pharma-
kologie und Toxikologie (LPT; Hamburg, Germany).
A total of 14 adult cynomolgus monkeys were included
in this study. ALX-0061 (0.4, 2 and 10 mg/kg) and its
non-half-life extended monovalent anti-IL-6R domain
(0.74 mg/kg) were administered on day 0 to three animals
(two animals in the 10 mg/kg dose group) via a single
intravenous bolus injection. Control animals (n = 3) re-
ceived formulation buffer as placebo. Starting 24 hours
after test item administration, all animals were injected
subcutaneously once daily for seven consecutive days with
recombinant hIL-6 (Gentaur) at 5 μg/kg.
Blood samples were taken pre-dose and up to 29 days
post-administration for purpose of PK, ADA, PD (CRP
and fibrinogen) and hematology (including platelet
counts). Bioanalytical determination of total ALX-0061
plasma concentrations was performed using a sandwich
ELISA. In brief, 96-well microtiter plates were coated with
a bivalent capturing anti-Nanobody Nanobody (Ablynx,
Gent, Belgium) and blocked with PBS plus 1 % casein
(Thermo Fisher Scientific, Waltham, MA). After transfer
of the calibrators, QC samples and study samples (1/10 di-
lutions in PBS plus 0.1 % casein) to the coated plate, the
plates were incubated with a biotinylated detection anti-
Nanobody Nanobody, followed by HRP-labelled streptavi-
din. Visualization was performed as described above.
Plasma concentrations of the monovalent anti-IL-6R
binding domain were also measured using a sandwich
ELISA. Neutravidin (Thermo Fisher Scientific, Waltham,
MA) and a biotinylated anti-Nanobody Nanobody were
used as capture, and Superblock T20 as blocking buffer.
After transfer of the calibrators, QC samples and study
samples (dilutions in PBS plus 0.1 % casein + hIL-6R for
complexation with target) to the coated plate, detection
was performed with the non-neutralizing mAb B-N12. The
HRP-labelled polyclonal rabbit anti-mouse immunoglobu-
lin (IgG) (DakoCytomation, Glostrup, Denmark) was used
for visualization as described above. Data were expressed as
ng/ml and individual plasma concentration-time profiles
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using the pre-programmed model 201 within WinNonlin
version 5.1 (Pharsight, St Louis, MO, USA). The area under
the curve (AUC) and derived PK parameters were calcu-
lated with the linear-up/log down trapezoidal rule.Collagen-induced arthritis study in rhesus monkeys
This study was conducted at the facilities of the Biomedical
Primate Research Centre (BPRC; Rijswijk, the Netherlands)
in accordance with the Dutch law on animal experimenta-
tion. The study protocol and experimental procedures were
reviewed and approved by the Experimental Animal Care
and Use Committee of the BPRC (approval number DEC
#633) before the experiments started.
CIA-susceptible adult, healthy rhesus monkeys (Macaca
mulatta; BPRC) were selected on basis of the absence
of the dominant major histocompatibility complex
(MHC) class I resistance marker Mamu-B26, as identi-
fied by serotyping [17–19]. CIA was evoked by
immunization with 5 mg of chicken type II collagen
(MD Biosciences, St Paul, MN, USA), dissolved in 0.1 M
acetic acid to a final concentration of 10 mg/mL, and mixed
with an equal volume of complete Freund’s adjuvant (CFA;
DIFCO, Detroit, MI, USA).
A total of 19 animals were distributed over three
groups. Prophylactic treatment was started before the
onset of disease seven days after immunization. ALX-
0061 (7.5 mg/kg; N = 7), TCZ (10 mg/kg; N = 7) or
placebo (N = 5) was administered weekly, starting seven
days after immunization. The dose for TCZ (10 mg/kg)
was based on published data in a similar model in cy-
nomolgus monkeys [20]. Test substances were given as
an intravenous bolus injections. Formulation buffer of
ALX-0061 was used as a placebo.
The animals were sedated twice weekly for assess-
ment of clinical arthritis using the parameters of joint
swelling, erythema, weight loss and impairment of
movement. All clinical signs were graded on a scale
from 0 to five, and resulted in an integrated discom-
fort clinical score using a semi-quantitative scale, as
described previously [21–23]. The planned follow up
period was 70 days after CIA induction, with animals
being prematurely removed from the experiment for
animal welfare reasons upon development of a pre-
defined integrated discomfort clinical score [22, 23].
In addition to the clinical scoring, surrogate and bio-
chemical disease parameters were determined twice
weekly including body weight, swelling score and
serum CRP levels, as described previously [21–23].
Blood was collected throughout the study for monitor-
ing drug concentrations, and total sIL-6R was used as
a biomarker indicating the presence of active drug,
using ELISA-based assays as described above.Results
Design of ALX-0061
ALX-0061 is a half-life extended bispecific Nanobody
consisting of two sequence-optimized variable domains
of llama-derived VHH antibodies, genetically fused via
nine linked amino acids (GGGGSGGGS). One domain
provides the target specificity of ALX-0061, namely rec-
ognition of IL-6R, while the other interacts with HSA
and mediates the half-life extension of ALX-0061. This
constitutes a minimized design yielding a small two-
domain structure with a molecular weight of 26 kDa.
For comparison, a conventional therapeutic monoclonal
antibody will comprise of 12 domains with a molecular
weight of approximately 150 kDa [24].
The anti-IL-6R VHH was obtained from a phage dis-
play library derived from a llama immunized with re-
combinant hIL-6R and following screening for sIL-6R
binding and neutralization. Humanization of the VHH
was performed yielding a Nanobody domain with more
than 90 % homology to the human germline consensus
sequence in the framework regions. In order to further
improve target affinity, this domain was submitted to
two rounds of affinity maturation.
Kinetic parameters for binding of the parental and of
five affinity matured variants to sIL-6R were determined
via SPR. Due to the very slow dissociation of the affinity
matured variants, only approximate values of the kinetic
parameters could be derived. Affinity maturation re-
sulted in an approximate 200-fold gain in affinity for
sIL-6R compared to the parental Nanobody. Formatting
of the selected lead anti-IL-6R domain to the HSA bind-
ing domain resulted in ALX-0061. The complete process
from immunization to final format of ALX-0061 is pre-
sented in more detail in Fig. 1.In vitro characterization of ALX-0061
Due to the slow dissociation of ALX-0061 from hsIL-6R,
the SPR methodology was not sufficiently sensitive for a
reliable affinity determination. Therefore, the Gyrolab
microfluidic-based analysis platform was used as an al-
ternative platform to determine the equilibrium dissoci-
ation constant (KD) of ALX-0061 for IL-6R. The Gyrolab
represents a novel platform alternative to determine
compound affinity with, as its main advantage, the use
of solution-based, and thus surface-free, measurements
of unmodified molecules. An enhanced sensitivity can be
obtained due to the increased surface-to-volume ratio.
Using the Gyrolab Bioaffy microfluidic system, the KD of
ALX-0061 for hsIL-6R was determined to be 0.19 ± 0.08
pM (n = 7). Addition of saturating concentrations of 50
nM HSA had no significant effect on the affinity of
ALX-0061 for hsIL-6R (data not shown). Affinity deter-
mination of ALX-0061 for HSA (mediated by its
Fig. 1 Development process of ALX-0061. After immunization of a llama with recombinant hIL-6R, a Nanobody phage display library was generated and
screened for anti-IL-6R lead candidates. Optimization of the selected lead candidate consisted of humanization, yielding a Nanobody domain with more
than 90 % homology to the human germline consensus sequence in the framework regions, and affinity maturation. Formatting of the
selected lead anti-IL-6R domain to the HSA binding domain resulted in ALX-0061. After manufacturing in Pichia pastoris, ALX-0061 was
tested in vitro and in vivo. hIL-6R: human interleukin-6 receptor; HLE: half-life extension; HSA: human serum albumin; sIL-6R: soluble IL-6R;
VHH: heavy-chain-only antibodies
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ing a KD value of 22 nM.
The effect of ALX-0061 on target neutralization was
further characterized in vitro using three functional assays
that measure the interaction of IL-6 with its cognate
receptor. In order to analyze possible effects of albumin
binding on the IL-6R-blocking activity of ALX-0061,
assays were also performed in the presence of saturating
concentrations of HSA. In a first ELISA-based sIL-6R
neutralization assay, ALX-0061, in a concentration-
dependent manner, completely blocked the interaction of
recombinant hIL-6 to recombinant hsIL-6R. The presence
of HSA had no overt effect on the potency of ALX-0061
in this assay (Fig. 2a; Table 1). A similar observation was
made in the plasma potency assay, which was used to
evaluate the ability of ALX-0061 to prevent binding of
recombinant hIL-6 to endogenous sIL-6R in the presence
of endogenous HSA, in a pool of human plasma. Obtained
potency values were comparable in both assays (Table 1).
In a cell-based assay using human hematopoietic TF-1
cells, inhibition of IL-6-induced proliferation mediated by
mIL-6R was analyzed. Also in this assay, ALX-0061, in a
concentration-dependent manner, completely blockedproliferation of the TF-1 cells (Fig. 2b; Table 1). In contrast
to what was observed in the ELISA-based sIL-6R
neutralization assay, the presence of saturating concentra-
tions of HSA had an effect, although minor (two to three
fold), on the potency of ALX-0061 in this cell-based assay.
In the absence of IL-6, TF-1 cell proliferation was not
induced by ALX-0061 (Fig. 2b), confirming that ALX-
0061 has no agonistic effect on TF-1 cells.
Species cross-reactivity of ALX-0061
Both specificities of ALX-0061 (albumin binding and IL-6R
blocking) were preserved in monkey species to enable non-
clinical in vivo testing. Cross-reactivity was demonstrated
for albumin of cynomolgus monkey, guinea pig, mouse and
rat species (data not shown). Cross-reactivity of the IL-6R-
targeting domain for membrane-bound and soluble forms
of IL-6R from different species was evaluated in vitro by
different approaches, including flow cytometry analysis,
immunohistochemistry, and binding ELISAs. ALX-0061
was shown to be cross-reactive with cynomolgus and rhesus
monkey species, but not with mouse, rat, and guinea pig
sIL-6R. These data are summarized in an additional table
(Additional file 1: Table S1).
Fig. 2 Inhibition profiles of ALX-0061 in an sIL-6R-based (a) and an mIL-6R-based (b) assay. ALX-0061 was pre-incubated with recombinant hIL-6 and
recombinant hIL-6R, in the presence or absence of HSA, followed by the capture of hIL-6R on ELISA plates coated with a non-neutralizing anti-IL-6R
mAb. IL-6 that remained in complex with IL-6R was detected using a biotinylated anti-IL-6 tool, and subsequent visualized with streptavidin-
HRP. An example experiment for a neutralization experiment is presented in (a). Human TF-1 cells were pre-incubated with a dilution series of ALX-0061 in
the presence of HSA, after which proliferation was induced with 2 ng/mL of IL-6. After 72 hours of incubation, cell proliferation was assessed by incorporation
of 3H-thymidine. ALX-0061 did not induce proliferation in the absence of IL-6 (b). Symbols depict mean responses; error bars represent ± SD of triplicate
samples within the experiment. ELISA: enzyme-linked immunesorbent assay; h: human; HRP: horseradish peroxidase; HSA: human serum albumin; IL-6:
interleukin-6; IL-6R: IL-6 receptor; mAb: monoclonal antibody; mIL-6R: membrane IL-6R; OD: optical density; SD: standard deviation; sIL-6R: soluble IL-6R
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of ALX-0061
The influence of half-life extension via albumin binding was
investigated in an IL-6-induced inflammation model in cy-
nomolgus monkeys. The plasma-concentration time profiles
after a single intravenous administration of 0.74 mg/kg of
the monovalent anti-IL-6R domain or 0.4 mg/kg, 2 mg/kg,
or 10 mg/kg ALX-0061 are shown in Fig. 3, and the corre-
sponding PK parameters calculated by NCA are displayed in
Table 2.
The PK profile of the monovalent anti-IL-6R domain
after a single intravenous administration showed a biphasic
decline with a short apparent terminal half-life of 4.3 hours
and a mean clearance of 3,971 mL/(day/kg). In contrast,
the PK profiles of ALX-0061 showed a triphasic decline: a
distribution phase was followed by a dominant elimination
phase and a more rapid terminal elimination phase, and
after increasing the dose from 0.4 to 10 mg/kg, the esti-
mated clearance of ALX-0061 decreased (9.00 to 24.8 mL/
(day/kg)) compared to its monovalent anti-IL-6R domain.
The dominant elimination half-life of ALX-0061 increasedTable 1 In vitro characterization of ALX-0061 using functional neutra
Assay Target
sIL-6R neutralization potency ELISA recombinant sIL-6R
Plasma potency ELISA endogenous sIL-6R
TF-1 cell-based proliferation assay mIL-6R
In vitro activity of ALX-0061 was assessed using three different assays. The mean IC
indicated between brackets. 15 μM HSA should saturate ALX-0061 concentrations in
serum albumin; IC50: half minimal (50 %) inhibitory concentration; IL-6: interleukin-
deviation; sIL-6R: soluble IL-6Ralong with the dosage (1.7 days after 0.4 mg/kg ALX-0061
to 6.6 days after 10 mg/kg ALX-0061), and the drug expos-
ure increased more than dose-proportionally (Table 2, PK
parameter AUCinf). The mean volume of distribution at a
steady state ranged from between 43 and 83 mL/kg for the
three ALX-0061 doses, suggesting that drug distribution is
limited to the vascular and extracellular space, as generally
described for monoclonal antibodies [25]. In summary,
prolonged exposure was achieved with ALX-0061, whereas
the non-half-life extended anti-IL-6R domain was rapidly
cleared. These data provide evidence for the in vivo effect
of half-life extension through binding to serum albumin.
Pharmacodynamic activity of ALX-0061 in healthy
cynomolgus monkeys
The prolonged exposure through albumin binding as de-
scribed above translated into durable PD effects as was
demonstrated in a PK/PD study. ALX-0061 showed a dose-
dependent effect in cynomolgus monkeys (single intraven-
ous doses ranged from 1 to 100 mg/kg) on: (i) the maximal
total sIL-6R (that is, free sIL-6R and sIL-6R in complexlization assays
IC50 (nM) without HSA IC50 (nM) with 15 μM HSA
0.07 ± 0.02 (n = 5) 0.06 ± 0.01 (n = 3)
NA 0.26 ± 0.03 (n = 3)
0.29 ± 0.03 (n = 3) 0.77 ± 0.18 (n = 3)
50 ± SD is shown of multiple experiments, with the number of experiments
these experiments. ELISA: enzyme-linked immunesorbent assay; HSA: human
6; IL-6R: IL-6 receptor; mIL-6R: membrane IL-6R; NA: not applicable; SD: standard
Fig. 3 Plasma-concentration time profiles of anti-IL-6R Nanobodies after a single intravenous administration in cynomolgus monkeys. At day 0, animals
received the monovalent non-half-life extended anti-IL-6R domain at 0.74 mg/kg (n = 3) or ALX-0061 at 0.4 (n = 3), two (n = 3), or 10 (n = 2) mg/kg,
before daily subcutaneous injection with recombinant hIL-6 at 5 μg/kg for seven consecutive days. Mean (±SD) plasma-concentration time profiles of
the Nanobodies are shown on a logarithmic scale. IL-6R: interleukin-6 receptor; SD: standard deviation
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period, (ii) the duration of baseline increased total sIL-6R
concentrations, and (iii) the duration of the suppression of
free sIL-6R (Fig. 4). In general, total and free sIL-6R con-
centrations returned to baseline levels after a given time,
dependent on the dose. An association between an increase
in total sIL-6R levels and a decrease in free sIL-6R levels
was observed with longest elevation and suppression re-
spectively in the highest dose group.
The total sIL-6R concentration was shown to be a sensi-
tive and timely marker for possible accelerated elimination
of ALX-0061. This could be deduced from PK/PD data in
animals showing aberrant PK profiles, most possibly due to
the emergence of neutralizing and/or clearing ADA. Two
animals in the highest dose group (100 mg/kg) showed a
marked accelerated decrease in their ALX-0061 concentra-
tions starting around day 63 (Fig. 5a), accompanied with a
fast decline in total sIL-6R levels starting at the same timeTable 2 Pharmacokinetic parameters of the non-half-life extended a
Test item N t1/2, dominant t1/
(day) (d
Mean CV % M
Non-half-life extended domain i.v. 0.74 mg/kg 3 - - 0
ALX-0061 i.v. 0.4 mg/kg 3 1.73 11 0
ALX-0061 i.v. 2 mg/kg 3 5.00 15 1
ALX-0061 i.v. 10 mg/kg 2 6.61 11 -
At day 0, three animals received the non-half-life extended domain at 0.74 mg/kg o
subcutaneous injection with recombinant hIL-6 at 5 μg/kg for seven consecutive da
non-compartmental analysis
i.v. = intravenous; t1/2, dominant = dominant elimination half-life; t1/2, terminal = termin
time zero to infinity; CL = total body clearance; Vss = volume of distribution at stead(Fig. 5b). Using a screening and confirmation assay, ADA
was detectable in these animals within the same time frame,
confirming possible neutralizing and/or clearing immuno-
genicity (data not shown).
In vivo efficacy in a cynomolgus monkey model of human
interleukin-6-induced inflammation
In vivo efficacy of ALX-0061 (administered at 0.4, 2, or
10 mg/kg) was first examined in a cynomolgus monkey
model of hIL-6-induced inflammation. Plasma concen-
tration of CRP, fibrinogen, and platelet numbers were
monitored in the primates as inflammation parameters
from the first hIL-6 injection until day 14. ALX-0061
conveyed in vivo biological activity, as indicated by a
dose-dependent and complete inhibition of the three
acute phase response parameters (Fig. 6a-c).
CRP concentrations increased rapidly after the start of
hIL-6 injections in placebo-treated animals, and reachednti-IL-6R domain and ALX-0061 in cynomolgus monkeys
2, terminal AUCinf CL Vss
ay) (μg/day/ml) (ml/day/kg) (ml/kg)
ean CV % Mean CV % Mean CV % Mean CV %
.18 3 0.19 2 3971 2 227 27
.53 6 16.3 14 24.8 14 42.8 8
.44 9 193 5 10.4 6 53.7 7
- 1136 21 9.00 21 82.7 10
r ALX-0061 at 0.4, 2, or 10 mg/kg as a single intravenous dose, before daily
ys. Pharmacokinetic parameters were calculated using
al elimination half-life; AUCinf = area under the concentration-time curve from
y state. CV %: coefficient of variation; N: number of animals
Fig. 4 Effect of ALX-0061 on total (a) and free (b) sIL-6R plasma levels in cynomolgus monkeys. Per group, mean plasma concentrations of either
biomarker ± SD are shown (n = 2 for vehicle group; n = 3 for dosing groups). Placebo or ALX-0061 at given doses were administered at day 0 as
a single intravenous administration to non-stimulated cynomolgus monkeys. n: number of animals; SD: standard deviation; sIL-6R: soluble IL-6R
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(Fig. 6a). This effect plateau was sustained during the
seven days of hIL-6 administrations. The hIL-6-induced
increase in CRP was completely inhibited in the high
(10 mg/kg) and middle (2 mg/kg) dose groups of ALX-
0061. CRP induction was inhibited for seven days in the
low (0.4 mg/kg) dose group, and levels were increased
compared to baseline on day eight only. CRP concentra-
tions returned to baseline levels once administration of
hIL-6 was discontinued.
Fibrinogen concentrations increased five-fold compared
to baseline in placebo-treated animals (Fig. 6b). Compared
to the increase in CRP, the rise in fibrinogen levels exhibited
a slower onset, and peaked five days after the first hIL-6 ad-
ministration. In the high and middle ALX-0061 dose
groups, fibrinogen induction by hIL-6 was completely
inhibited. A minor increase in fibrinogen was observed in
the low ALX-0061 dose group on day eight, which reachedFig. 5 Total sIL-6R as PD marker for active drug exposure. Individual observ
shown after a single intravenous administration of 100 mg/kg ALX-0061 in
soluble IL-6Ra maximum of two to three times the baseline level.
Fibrinogen concentrations returned to baseline after dis-
continuation of hIL-6 treatment.
The number of platelets increased steadily in
placebo-treated animals upon administration of hIL-6,
and kept increasing after the last administration of hIL-
6 at day seven, until the end of the experiment on day
14 (Fig. 6c). Some induction in platelet count was ob-
served in the low dose group of ALX-0061, starting in
all animals between day eight and 14, indicative of a
suboptimal effect at this dose: maximal observed plate-
let counts in this group were around 120 to 150 % of
baseline levels, compared to 140 to 190 % for placebo-
treated animals. The effect of hIL-6 on platelet count
was completely suppressed in the high and middle dose
groups treated with ALX-0061. Lower and non-
continuous exposure, such as those conferred by dosing
the non-half-life extended variant, did not result ined ALX-0061 (a) and total sIL-6R (b) concentration-time profiles are
non-stimulated cynomolgus monkeys. PD: pharmacodynamic; sIL-6R:
Fig. 6 Acute phase response parameters in a cynomolgus monkey model of inflammation. Effect of a single dose of ALX-0061 (0.4, 2, or 10 mg/
kg) on different acute phase response parameters is shown. (a) C-reactive protein plasma levels. (b) Fibrinogen plasma levels. (c) Platelet counts.
Data were processed as follows: group mean values were calculated, error bars represent SEM, and platelets concentrations were normalized relative to
individual baseline levels to reduce the inter-animal variation. CRP: C-reactive protein; SEM: standard error of mean
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pected (data not shown).Collagen-induced arthritis model in rhesus monkeys
In vivo efficacy of ALX-0061, with respect to manifesta-
tions of clinical symptoms of RA, was further evaluated
in a CIA model in rhesus monkeys, with inclusion of
TCZ as a positive control. Acute or ‘early’ responders
were first identified in the study based on the time inter-
val between arthritis induction and a sharp increase in
CRP or clinical score defined by: (i) an acute phase re-
sponse of CRP (>50 mg/L) between day 10 to 14, or (ii)
a clinical score of five before day 24 [22, 26]. Because of
the violent and rapid onset of serious disease not reflect-
ive of a treatable clinical situation, early responders (four
out of 19 animals) were excluded from certain analyses
(Table 3).
It became apparent after PK/PD and immunogenicity
assessment that interpretation of results was confounded
by the appearance of immune responses that influenced
the therapeutic effect of both TCZ and ALX-0061. Neu-
tralizing or clearing ADA affected free active drug con-
centrations from day 20 onwards (that is, 13 days after
the first drug administration). Both treatment groups
were affected by ADA to the same extent (Table 3).
Total sIL-6R levels increased rapidly after the first drug
administration in all ALX-0061- or TCZ-treated animals,
indicating the presence of active drug. However, total
sIL-6R concentrations returned to baseline levels for five
out of seven animals from either group, upon emergence
of neutralizing and/or clearing ADAs (between day 24
and 34). Total sIL-6R levels remained elevated through-
out the study in only two animals treated with ALX-
0061 (R02055 and R05042) and two animals treated with
TCZ (R05059 and 95031) (Fig. 7a,b), indicating exposureto active drug throughout the observation period in a
minority of animals treated with ALX-0061 and TCZ.
Several specific disease markers were measured in this
study to obtain independent quantitative information on
the systemic disease status, including CRP levels. Serum
CRP levels are increased during the acute phase re-
sponse of systemic inflammation, and directly reflect the
intensity of the inflammatory process. IL-6R inhibition
by ALX-0061 and TCZ resulted in a suppression of the
CRP response, similar as was seen in the IL-6-induced
inflammation study (Fig. 8a-c). Analysis of CRP plasma
concentrations using normalized AUC values (AUCnorm)
to account for different follow-up periods demonstrated
that, in the placebo group, significantly higher CRP con-
centrations were measured compared to treatment with
TCZ (P = 0.015) or ALX-0061 (P = 0.011). No significant
difference was noted between animals with or without
interfering ADA, most likely because CRP is an early re-
sponse marker, which is induced before the possible
emergence of neutralizing ADA.
A pronounced reduction in the clinical severity scores, or
a transient increase in the severity score with ensuing im-
provement of the condition, was observed in the animals
which were exempt from an interfering immune response,
and as a result, demonstrated an exposure to active drug
throughout the observation period (Fig. 8d-f). Details of the
obtained data are given in Table 3.
Discussion
We present the novel biotherapeutic ALX-0061, consisting
of two domains only, which we show suffices to confer
favorable pharmacology in vitro and in vivo. ALX-0061 tar-
gets IL-6R and is currently in clinical development for the
treatment of autoimmune diseases, such as RA [27]. Several
compounds targeting the IL-6 pathway are currently in
clinical development as a testament to the importance of
Table 3 Overview of results obtained in the CIA study in rhesus monkeys


















at day of sacrifice
or day 70
Placebo 95020 24 547.5 NA 39 No NA -23 % 8
Placebo R05029 21 191.5 NA 44 No NA -20 % 12.5
Placebo R05053 24 535.6 NA 52 No NA -25 % 37
Placebo R05058 17 547.2 NA 38 No NA -25 % 14
Placebo R05073 14 643.1 28 29 Yes (CRP) NA
7.5 mg/kg ALX-0061 R00060 17 151.6 21 22 Yes (Cl Sc) No
7.5 mg/kg ALX-0061 R01016 35 101.9 35 34 No Yes (Day 34)
7.5 mg/kg ALX-0061 R02055 NA <50 NA 70 No No -10 % 0
7.5 mg/kg ALX-0061 R03014 17 128.1 NA 49 No Yes (Day 28)
7.5 mg/kg ALX-0061 R05012 21 188.9 NA 44 No Yes (Day 34)
7.5 mg/kg ALX-0061 R05042 NA <50 NA 70 No No -15 % 2
7.5 mg/kg ALX-0061 R06003 17 50.6 17 17 Yes (Cl Sc) No
10 mg/kg tocilizumab 95031 NA <50 NA 70 No No +4 % 0
10 mg/kg tocilizumab BB226 24 367.3 28 28 No Yes (Day 28)
10 mg/kg tocilizumab R04042 28 448.1 31 31 No Yes (Day 28)
10 mg/kg tocilizumab R05059 NA <50 NA 70 No No +6 % 0
10 mg/kg tocilizumab R05061 21 453.0 31 31 No Yes (Day 24)
10 mg/kg tocilizumab R05089 28 161.7 NA 70 No Yes (Day 28)
10 mg/kg tocilizumab R05090 21 171.1 21 21 Yes (Cl Sc) Yes (Day 21)
Treatment was started seven days after sensitization with chicken collagen type II. Animals were administered weekly for six consecutive weeks by intravenous bolus injection. ALX-0061 was given at 7.5 mg/kg, and TCZ
at 10 mg/kg. Data were processed as follows: body weight was normalized to pre-dose weight (day 0); Body weight and swelling score are not included for early responders and animals which showed a clearing and/or
neutralizing ADA response. Early responders were identified via CRP or clinical score. Animals which had active exposure throughout the study (that is, no neutralizing and/or clearing ADA) are highlighted in bold
aStudy day that a CRP level of more than 50 mg/ml was measured for the first time, starting after day 10 (subsiding of the acute CFA response); increasing CRP levels after day 10 are interpretable as a sign of disease severity
bMaximum CRP values measurable for the given animal after day 10; these concentrations are interpretable as a measure of disease severity
cStudy day on which a maximum clinical score of five was reported; this is interpretable as a measure of disease severity, with early onset being a hard-to-treat disease course
dAnimals with high discomfort scores had to be euthanized during the study period
ADA: anti-drug antibodies; CFA: complete freund’s adjuvant; CIA: collagen-induced arthritis; Cl Sc: clinical score; CRP: C-reactive protein; ID: identification; NA: not applicable; PK: pharmacokinetics; sIL-6R: soluble














Fig. 7 Total sIL-6R serum levels in the CIA study in rhesus monkeys. Curves depict results from individual animals. Acute responders and animals
with neutralizing and/or clearing ADAs are indicated in black. Colored lines indicate animals with active drug levels throughout the entire study.
Animals with high discomfort scores had to be euthanized during the study period. (a) Total sIL-6R levels after 7.5 mg/kg ALX-0061 treatment.
(b) Total sIL-6R levels after 10 mg/kg TCZ treatment. ADA: anti-drug antibodies; CIA: collagen-induced arthritis; sIL-6R: soluble interleukin-6
receptor; TCZ: tocilizumab
Fig. 8 Effect of treatment on CRP and clinical outcome in the CIA study in rhesus monkeys. Curves depict results from individual animals. Acute
responders and animals with neutralizing ADAs are indicated in black. Colored lines indicate animals with active drug levels throughout the
entire study. Animals with high discomfort scores had to be euthanized during the study period. (a-c) Development of acute phase response as
measured by CRP production. (d-f) Clinical score was calculated based on clinical signs, soft tissue swelling, body temperature, and body weight.
Clinical score was monitored twice weekly. (a, d) Placebo; (b, e) 7.5 mg/kg ALX-0061; (c, f) 10 mg/kg TCZ ADA: anti-drug antibodies; CIA: collagen-
induced arthritis; CRP: C-reactive protein; TCZ: tocilizumab
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mode of action has been clinically validated by the develop-
ment of TCZ, a monoclonal antibody against IL-6R, mar-
keted as RoActemra® in Europe and Actemra® in the US
and elsewhere. TCZ demonstrated good clinical responses
and an acceptable safety profile in clinical trials, and con-
tinues to demonstrate this in daily clinical practice. The
safety data are in some respects similar to those seen with
other biologics in RA, including infections, although some
IL-6 pathway-dependent effects are also seen, including a
decrease in neutrophils and an increase in lipids, without a
distinct cardiovascular safety risk. ALX-0061 is a bispecific
Nanobody that has been designed for monovalent binding
to hIL-6R, while its half-life in circulation is controlled by
genetic fusion to a domain binding to HSA, one of the most
abundant proteins in the blood. The results of this study
demonstrate that this minimized structure of 26 kDa suffices
to convey effective IL-6R neutralization in vitro and in vivo.
Compound-binding properties, such as affinity, and
biological activity next to target selectivity contribute to
the highly specific and competitive profile of therapeutic
antibodies. ALX-0061 was purposely designed as a high-
affinity binder to its receptor through affinity improve-
ment in vitro, in particular to the soluble form of IL-6R.
Typical Nanobody characteristics (such as small size,
single-domain nature, and robust folding) make format-
ting and the construction of second-generation libraries
based on a previously selected Nanobody more straight-
forward [14], which can be exploited to optimize binding
characteristics to a given antigen more efficiently. The
affinity of Nanobodies can be improved by generating
bivalent Nanobody constructs that take advantage of
avidity effects, without affecting the intrinsic affinity be-
tween a single Nanobody domain and its antigen, or by
in vitro affinity maturation. In case of ALX-0061, ap-
proximately a 200-fold gain in affinity for sIL-6R com-
pared to the parental Nanobody was achieved through
affinity maturation. The KD of ALX-0061 for IL-6R was
quantified to be 0.19 ± 0.08 pM. To our knowledge, only
a few studies describing a sub-picomolar affinity for
therapeutic antibodies have been published [28, 29]. This
research demonstrates that a single Nanobody target
binding domain suffices and confers equal or higher af-
finity binding compared to published data of therapeutic
monoclonal antibodies, where bivalent binding is
conferred by four domains [24]. The high affinity of
ALX-0061 translated in a high potency in ELISA-based
neutralization assays for sIL-6R and in a cell-based
neutralization assay for mIL-6R. Biologics with affinities
in the femtomolar range may provide significant im-
provements in pharmacological activity, depending on
the biological characteristics of the antigen, such as
in vivo target and ligand concentration, as well as affinity
for the ligand and disposition kinetics.The affinity of ALX-0061 for HSA was determined via
SPR, resulting in a KD of 22 nM. This affinity for HSA
can be expected to result in a high fraction of ALX-0061
bound to serum albumin in vivo considering the high
abundance of albumin (approximately 640 μM in
humans [30]). The albumin-targeting domain of ALX-
0061 was confirmed to bind to cynomolgus monkey
serum albumin, and thus was expected to provide per-
sistent exposure: albumin is rescued from glomerular fil-
tration and unspecific pinocytosis by binding to the
neonatal Fc receptor (FcRn) in a similar way as anti-
bodies, although an alternative binding site is used [31].
Results presented here confirmed that ALX-0061 shows
PK properties in this species consistent with albumin-
mediated FcRn recycling, while the non-half-life ex-
tended anti-IL-6R domain had only a short apparent ter-
minal half-life of 4.3 hours. Presumably, the non-half-life
extended domain is rapidly cleared via the kidneys, as its
molecular weight of 13 kDa is expected to be well below
the molecular weight cut-off for glomerular filtration,
which is estimated at 70 kDa in humans [32, 33]. The
mean clearance of the non-half-life extended domain
was indeed in the same range as the glomerular filtration
rate reported in monkeys (5 kg) of 2,995 mL/(day/kg)
[34]. In contrast, the estimated clearance of
ALX-0061 after single intravenous doses of 0.4 to
10 mg/kg was much lower, and can be attributed to
binding of the HSA binding domain to serum albumin.
Furthermore, the estimated dominant half-life of ALX-
0061 after 2 and 10 mg/kg intravenous administration
(5.0 and 6.6 days, respectively) was similar to the esti-
mated half-life of cynomolgus monkey serum albumin of
5.6 days, calculated for a 3 kg typical cynomolgus mon-
key, based on the relationship between albumin half-life
and body weight (3.75/Body Weight(kg)0.368) described
by Nguyen et al. [35]. A similar triphasic decline as was
seen for ALX-0061 was also described for TCZ, whereby
the rapid terminal elimination phase could be attributed
mainly to target-mediated drug elimination due to IL-6R
binding, which was saturated at high drug levels result-
ing in a lower overall clearance dominated by a linear
non-saturable clearance (dominant elimination phase)
[36]. Due to this non-linear PK behaviour of ALX-0061,
estimated drug exposure and apparent half-lives were
time- and dose-dependent.
The pharmacological activity of ALX-0061 towards
IL-6R of the cross-reactive species cynomolgus and
rhesus monkey was confirmed in vivo in two relevant
non-human primate models. In an acute cynomolgus
monkey model of hIL-6-induced inflammation, deregu-
lation of IL-6R-dependent biomarkers was studied after
prophylactic treatment and subsequent administration
of recombinant hIL-6. ALX-0061 showed a dose-
dependent and complete prevention of induction of
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ministration (CRP, fibrinogen, and platelet count), com-
parable to the results reported for TCZ in a similar
model [37].
ALX-0061 was further evaluated in a rhesus monkey
CIA model, in comparison to placebo and with TCZ as
positive control. In this model, the induced disease
closely resembles the pathological hallmarks of RA, in-
cluding synovitis and joint destruction [23], and shows
characteristic features of human RA as defined by the
American Rheumatism Association criteria [23, 38].
Mamu-B26 negative animals were selected before treat-
ment start as rhesus monkeys with this genotype are
highly susceptible for the inflammatory responses fol-
lowing collagen type II sensitization, and by pre-
selection for this genotype, a CIA prevalence of >95 %
can be achieved [17, 18, 23]. During the study, it became
apparent from PK/PD and immunogenicity assessments
that results in this particular model were complicated by
the appearance of immune responses interfering with
drug concentrations, and consequently therapeutic ef-
fect, from day 20 onwards (that is, 13 days after the first
drug administration). All treatment groups were affected
alike, and only two out of seven animals in the ALX-
0061 group and two out of seven animals in the TCZ
group remained available for full examination over the
entire length of the study. Similar findings were reported
in studies with other experimental therapeutic anti-
bodies, such as daclizumab (anti-IL-2Rα) and PDL241
(anti-CD319). First, ADA were detected between 10 and
14 days in a prophylactic experiment [39], which was
much faster compared to a study in naïve cynomolgus
monkeys [40]. Moreover, the ADA titers were generally
about five to 10 fold higher in the rhesus model com-
pared to the naïve cynomolgus monkeys, and had a high
impact on the plasma daclizumab levels [39].
In the PDL241 study, the development of a strong
neutralizing ADA response was also observed in the ma-
jority of monkeys treated with the monoclonal antibody,
with reduced exposure and strong infusion reactions as
a consequence [19]. It is conceivable that in this rhesus
model, the Mamu-B26 negative genotype, possibly in
combination with the complete Freund’s adjuvant in the
inoculum, renders animals immunologically hypersensi-
tive, as it does with chicken collagen type II. Although
this immunogenic potential may depend on the class of
drugs used and its mode of action, such as the anti-
CD28 compound FR104 prevented the development of
neutralizing antibodies [41], results obtained for biother-
apeutics in the model need to be interpreted with care.
An alternative CIA model in cynomolgus monkeys has
been described and was used previously for TCZ
[13, 20]. At the time, this model was not considered for
the testing of ALX-0061 mainly due to animal welfarereasons; there seemed to be a gender bias and a higher
number of monkeys is required as disease incidence is
lower compared to the rhesus model [42, 43]. In
addition, this model has also been described to be
greatly influenced by immunogenicity: most of the ani-
mals showed an immune response to TCZ, and anti-
TCZ antibodies had an impact on sIL-6R levels [13] or
efficacy [20]. Other models, such as rodent models,
could not be used due to lack of cross-reactivity.
In human RA, serum CRP levels are increased during
the acute phase response of systemic inflammation,
which precedes the onset of clinical symptoms and joint
eroding processes, and they directly reflect the intensity
of the inflammatory process [22, 23, 44]. Similar obser-
vations were made in the CIA model. Consequently,
CRP concentrations were measured as a direct marker
for early pathology. IL-6R inhibition by ALX-0061 or
TCZ suppressed CRP induction in most of the animals
as compared to the placebo group, and resulted in an
early biological response before the emergence of the
neutralizing ADA. As described above, the power of in-
terpretation of clinically relevant parameters of arthritic
disease was limited in this model. However, animals that
were unimpeded by interfering ADA showed marked
clinical treatment improvements. A similar subgroup
analysis for efficacy was performed in the PDL241 study
[19]. The effect of ALX-0061 on CRP seemed to be more
pronounced than its clinical effect. Although both CRP
and clinical effect are consequences of IL-6R inhibition,
they have their own variability, with clinical effect being
known to exhibit a higher variability compared to an
acute marker as CRP. As a consequence, large studies
would be necessary to draw statistical conclusions. CRP
and other acute phase markers are also directly located
in the IL-6 pathway as IL-6 is the main inducer of the
acute phase response [45], which was confirmed by the
results of the IL-6 induced inflammation model, while
more parameters come into play to have an effect on
clinical score. This was also seen with TCZ in clinical
trials, in which 8 mg/kg TCZ demonstrated a fast and
complete inhibition of CRP in most patients, although
only approximately 30 % of these patients achieved clin-
ical remission (DAS28 score <2.6) [46, 47].
The described non-human primate studies were used
to confirm in vivo pharmacology as discussed above, but
also to investigate possible biomarkers that may be
translated to the clinical situation. These were in par-
ticular CRP, fibrinogen, and platelet counts as efficacy
markers in a pathological condition, and total sIL-6R
concentrations (that is, free sIL-6R and sIL-6R in com-
plex with ALX-0061) as a PD marker both in healthy
and diseased subjects. The robustness and suitability of
sIL-6R levels as a proximal PD biomarker has been con-
firmed in the different nonclinical studies for ALX-0061
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[48]. A transient increase in circulating sIL-6R could be
observed upon administration of ALX-0061, reflecting
an accumulation of sIL-6R/drug complex that assumes
the long half-life of ALX-0061. The resulting sIL-6R in-
crease and the duration of the effect showed a clear
dose-dependent response. As ALX-0061 plasma concen-
trations decreased, concentrations of total sIL-6R de-
creased in parallel, as most of the total sIL-6R
constitutes receptor in complex with drug. This was
mirrored by suppression of free sIL-6R concentrations
during treatment, which return to baseline upon elimin-
ation of ALX-0061 from the circulation. Full suppression
of free sIL-6R concentrations demonstrated that mea-
sured total sIL-6R is indeed in complex with ALX-0061,
and thus inactive. The good inverse association between
total sIL-6R levels, free sIL-6R levels, and ALX-0061
concentrations confirmed that total sIL-6R is a valid and
sensitive biomarker, indicating the presence of active drug,
and a possible accelerated elimination of ALX-0061.
Conclusions
ALX-0061 is a 26 kDa, bispecific, two-domain Nano-
body targeting IL-6R and HSA simultaneously. This is
the first report on the in vitro and in vivo activity of a
Nanobody using this minimized design. ALX-0061 was
purposely designed as a high-affinity binder for its
therapeutic target through affinity maturation. Primary
pharmacology, defined as neutralizing both forms of
IL-6R (soluble and membrane-bound), was demon-
strated in vitro. These observations showed that the
high target affinity for IL-6R with a small biological en-
tity translated into a high potency. Half-life extension
of ALX-0061 was achieved by genetic fusion of the
anti-IL-6R domain to an anti-HSA domain, and favor-
able PK/PD properties were confirmed in vivo. Possible
biomarkers of effect were studied in different non-
human primate models that allow correlation of PK,
PD, and ADA. ALX-0061 is currently in clinical devel-
opment, with promising results from a phase I/II trial
in RA [27].
Additional file
Additional file 1: Table S1. Species cross-reactivity of ALX-0061 towards
sIL-6R and mIL-6R. Description of data: Species cross-reactivity was assessed
qualitatively and quantitatively using different assays. ALX-0061 showed equal
potency and binding towards IL-6R of non-human primates, and had a
confirmed effect in nonclinical in vivo models. These data are summarized in
Additional file 1: Table S1.
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